Positioning of HIV-protease inhibitors in clinical practice

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 1, 2012, Pages 10-18

  Andreoni, M ^a   Perno, C F ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Antiviral therapy; HIV; Protease inhibitors; Resistance; Virus replication

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RILPIVIRINE; RITONAVIR; RITONAVIR PLUS SAQUINAVIR;

ANTIVIRAL RESISTANCE; CLINICAL PRACTICE; DIARRHEA; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION;

DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HUMANS; PATIENT COMPLIANCE; TREATMENT FAILURE;

EID: 84859848829     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. LANGE J. A rational approach to the selection and sequencing of nucleoside/nucleotide analogues: a new paradigm. Antivir Ther 2001;6(Suppl 3):45-54. (Pubitemid 32938762)
2. RICHMAN DD. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 2000;32:866-867.
3. HO DD, NEUMANN AU, PERELSON AS, CHEN W, LEONARD JM, MARKOWITZ M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
4. WEI X, GHOSH SK, TAYLOR ME, VA JOHNSON, EMINI EA, DEUTSCH P, LIFSON JD, BONHOEFFER S, NOWAK MA, HAHN BH, SAAG M, SHAW GM. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
5. PATERSON DL, SWINDELLS S, MOHR J, BRESTER M, VERGIS EN, SQUIER C, WAGENER MM, SINGH N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30. (Pubitemid 30432540)
6. LOW-BEER S, YIP B, O'SHAUGHNESSY M V, HOGG RS, MONTANER J S G. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000;23:360-361. (Pubitemid 30327043)
7. FISCHL M, CASTRO J, MONROIG R, SCERPELLA E, THOMPSON L, RECHTINE D, THOMAS D. Impact of directly observed therapy on long-term outcomes in HIV clinical trials. Presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Abstract 528.
8. BANGSBERG DR, KAGAY CR, PORCO T, GRANT R, HOLODNIY M, CHARLEBOIS ED, ZOLOPA AR, NUGENT CONROY K, D GUZMAN D, MOSS AR. Modelling the relationship between adherence and accumulation of protease inhibitor (PI) drug resistance mutations based on objectively measured adherence and empirically derived relationships. Presented at: XI International HIV Drug Resistance Workshop; July 2-5, 2002; Seville, Spain.
9. Antivir Ther 2002;7(Suppl 1):S133. Abstract 160.
10. LUBER AD. Genetic barriers to resistance and impact on clinical response. MedGenMed 2005;7:69.
11. KATZENSTEIN DR, BOYLE BA, GALLANT JE, SQUIRES KE, ZOLOPA A. Current Management Challenges in HIV: Antiretroviral resistance, establishing a high genetic barrier. AIDS Read 2003;13:133-135, 138-142.
12. SHULMAN N, ZOLOPA A, HAVLIR D, HSU A, RENZ C, BOLLER S, JIANG P, RODE R, GALLANT J, ACE E, KEMPF DJ, SUN E. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother 2002;46:3907-3916. (Pubitemid 35403268)
13. DRAGSTED UB, GERSTOFT J, PEDERSEN C, PETERS B, DURAN A, OBEL N, CASTAGNA A, CAHN P, CLUMECK N, BRUUN JN, BENETUCCI J, HILL A, CASSETTI I, VERNAZZA P, YOILE M, FOX Z, LUNDGREN JD. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis 2003;188:635-642. (Pubitemid 37115175)
14. DRAGSTED UB, GERSTOFT J, YOULE M, FOX Z, LOSSO M, BENETUCCI J, JAYAWEERA DT, RIEGER A, BRUUN JN, CASTAGNA A, GAZZARD B, WALMSLEY S, HILL A, LUNDGREN JD; MAXCMIN2 TRIAL GROUP. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther 2005;10:735-743. (Pubitemid 41376853)
15. MALAN DR, KRANTZ E, DAVID N, WIRTZ V, HAMMOND J, MCGRATH D. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008;47:161-167. (Pubitemid 351172182)
16. MOLINA JM, ANDRADE-VILLANUEVA J, ECHEVARRIA J, CHETCHOTISAKD P, CORRAL J, DAVID N, MOYLE G, MANCINI M, PERCIVAL L, YANG R, THIRY A, MCGRATH D. Once-daily atazanavir/ritonavir versus twicedaily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372(9639):646-655.
17. MOLINA JM, ANDRADE-VILLANUEVA J, ECHEVARRIA J, CHETCHOTISAKD P, CORRAL J, DAVID N, MANCINI M, YANG R, MCGRATH D, ABSALON J. CASTLE: Atazanavir-ritonavir vs. lopinavir-ritonavir in antiretroviral-naïve HIV-1 infected patients: 96 week efficacy and safety. Paper presented at: 48th ICAAC/46th IDSA Meeting; October 25-28, 2008; Washington, DC. Abstract H-1250d.
18. ORTIZ R, DEJESUS E, KHANLOU H, VORONIN E, VAN LUNZEN J, ANDREADE-VILLANUEVA J, FOURIE J, DE MEYER S, DE PAUW M, LEFEBVRE E, VANGENEUGDEN T, SPINOSA-GUZMAN S. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008;22:1389-1397.
19. MILLS AM, NELSON M, JAYAWEERA D, RUXRUNGTHAM K, CASSETTI I, GIRAD PM, WORKMAN C, DIETYNCK I, SEKAR V, ABEELE C V, LAYREYS. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009;23:1679-1688.
20. ERON J JR, YENI P, GATHE J JR., ESTRADA V, DE JESUS E, STASZEWSKI S, LACKEY P, KATLAMA C, YOUNG B, YAU L, SUTHERLAND-PHILLIPS D, WANNAMAKER P, VAVRO C, PATEL L, YEO J, SHAEFER M. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006;368(9534):476-482. (Pubitemid 44160731)
21. PULIDO F, ESTRADA V, BARIL JG, LOGUE K, SCHEWE K, PLETTENBERG A, DUICULESCU D, YAU L, VAVRO C, LIM ML, PHARRO C. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks. HIV Clin Trials 2009;10:76-87.
22. ANTINORI A, MARCOTULLIO S, AMMASSARI A, ANDREONI M, ANGARANO G, CAROSI G, CINQUE P, D'ARMINIO MONFORTE A, DI PERRI G, ENSOLI B, FERRAZZI E, GALLI M, MASTROIANNI C, MATTEELLI A, MAZZOTTA F, MORONI M, PALÙ G, PUOTI M, PURO V, RIZZARDINI G, SAGNELLI E, SUTER F, VELLA S, LAZZARIN A. Italian Guidelines for the use of antiretroviral agents and diagnosticclinical management of HIV-1 infected persons. New Microbiol 2011;34:109-146.
23. GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS IN HIV-1-INFECTED ADULTS AND ADOLESCENTS. Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council (OARAC). Department of Health and Human Services. December 1, 2009.
24. WALMSLEY S, AVIHINGSANON A, SLIM J, WARD DJ, RUXRUNGTHAM K, BRUNETTA J, BREDEK U F, JAYAWEERA D, GUITTARI CJ, LARSON P, SCHUTZ M, RAFFI F. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 2009;50:367-374.
25. GUPTA R, HILL A, SAWYER AW, PILLAY D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008;47:712-722.
26. SANNE I, CAHN P, PERCIVAL L, PHANUPHAK P, KELLEHER T, GIORDANO M, PANTALEO G. Comparative results (phase II 48-week): BMS-232632, stavudine, lamivudine as HAART for treatment-naive HIV (+) patients (AI424-008). Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, Ill. Abstract 667.
27. NIETO-CISNEROS L, ZALA C, FESSEL WJ, GONZALES-GARCIA J, COHEN C, MCGOVERN R, ADLER E, MCLAREN C. Atazanavir (ATV) versus lopinavir/ritonavir (LPV/RTV) in patients with virologic failure to a protease-inhibitor (PI): 24-week results from BMS AI424-043. Presented at: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France. Abstract 117.
28. BADARO R, DE JESUS E, LAZZARIN A, JEMSEK J, CLOTET B, RIGHTMIRE A, THIRY A, WILBER R. Atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in patients with multiple virologic failures). Presented at: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France. Abstract 118.
29. SQUIRES KE, THIRY A, GIORDANO M. Atazanavir (ATV) QD versus efavirenz (EFV) QD with fixed-dose ZDV + 3TC BID: comparison of antiviral efficacy and safety 48-week results from BMS AI424-034 phase III pivotal study. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, Calif. Abstract H-10761.
30. COLONNO RJ, ROSE R, CIANCI C, ALDROVANDI G, PARKIN N, FRIBORG J. Emergence of atazanavir resistance and maintenance of susceptibility to other PIs is associated with an I50L substitution in HIV protease. Presented at: 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, Mass. Poster 597.
31. COLONNO RJ, THIRY A, LIMOLI K, PARKIN N. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother. 2003;47:1324-1333. (Pubitemid 36368593)
32. HIRSCH MS, BRUN-VEZINET F, CLOTET B, CONWAY B, KURITZKES DR, D'AQUILA RT, DEMETER LM, HAMMER SM, JOHNSON VA, LOVEDAY C, MELLORS JW, JACOBSEN DM, RICHMAN DD. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1:2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003;37:113-128. (Pubitemid 36836653)
33. DEMETER L. Drug resistance and the management of treatment failure. Presented at: 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 3, 2000; San Francisco, Calif. Abstract S32.
34. CINGOLANI A, ANTINORI A, RIZZO MG, MURRI R, AMMASSARI A, BALDINI F, DI GIAMBENEDETTO S, CAUDA R, DE LUCA A. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002;16:369-379. (Pubitemid 34165368)
35. HAUBRICH R, KEISER P, KEMPER C, WITT M, LEEDOM J, FORTHAL D, LIIBOWITZ M, HWANG J, SEEFRIED E, MC-CUTCHAN JA, HELLMANN N, RICHMAN D AND THE CCTG STUDY TEAM. CCTG 575: a randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy. Antivir Ther 2001;6(suppl 1):63.
36. WEGNER S, WALLACE M, TASKER S, ARONSON N, BLAZES D, TAMMINGA C, FRASER S, STEPHAN K, JAGODZINSKI L, VAHEY M, TRACY L, RINEHART A, GRAHAM N, HERTOGS K, BIRX D. Long-term clinical efficacy of resistance testing: results of the CERT trial. Antivir Ther 2002;7:S129. Abstract 158.
37. PEREZ-ELIAS MJ, GARCIA-ARATA I, MORENO S, MUNOZ V, SANTOS J, SANZ J, ABRAIRA V, ARRIBAS JR, GONZALES J, DRONDA F, ANTELA A, MORENO A, CASADO JL, PUMARES M, MARTÌ-BELDA P, GEIJO P AND THE REALVIRFEN STUDY GROUP. Baseline testing information given by a real phenotype (real Ph) or a virtual phenotype (virtual Ph) test in a randomized study (Realvirfen study): influence in final outcome. Antivir Ther 2002;7:S89. Abstract 109.